MA53043B2 - Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation - Google Patents

Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation

Info

Publication number
MA53043B2
MA53043B2 MA53043A MA53043A MA53043B2 MA 53043 B2 MA53043 B2 MA 53043B2 MA 53043 A MA53043 A MA 53043A MA 53043 A MA53043 A MA 53043A MA 53043 B2 MA53043 B2 MA 53043B2
Authority
MA
Morocco
Prior art keywords
methods
thieno
udp
pyridine derivatives
glycosyltransferase inhibitors
Prior art date
Application number
MA53043A
Other languages
English (en)
French (fr)
Other versions
MA53043A1 (fr
Inventor
Bradford Hirth
Elina Makino
Mark Munson
Sachin Maniar
Sungtaek Lim
Jr Robert H Barker
Mary A Cromwell
John JIANG
Yong-Mi Choi
Sukanthini Thurairatnam
Kwon Yon Musick
James Pribish
Michael Angelastro
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MA53043A1 publication Critical patent/MA53043A1/fr
Publication of MA53043B2 publication Critical patent/MA53043B2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA53043A 2018-10-01 2019-10-01 Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation MA53043B2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862739405P 2018-10-01 2018-10-01
PCT/US2019/054085 WO2020072504A1 (en) 2018-10-01 2019-10-01 Thieno[3,2-b]pyridine derivatives as udp glycosyltransferase inhibitors and methods of use

Publications (2)

Publication Number Publication Date
MA53043A1 MA53043A1 (fr) 2022-08-31
MA53043B2 true MA53043B2 (fr) 2024-05-31

Family

ID=68296740

Family Applications (1)

Application Number Title Priority Date Filing Date
MA53043A MA53043B2 (fr) 2018-10-01 2019-10-01 Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation

Country Status (15)

Country Link
US (1) US11098056B2 (cg-RX-API-DMAC7.html)
EP (1) EP3861000A1 (cg-RX-API-DMAC7.html)
JP (1) JP7545979B2 (cg-RX-API-DMAC7.html)
KR (1) KR102903997B1 (cg-RX-API-DMAC7.html)
CN (1) CN113423711B (cg-RX-API-DMAC7.html)
AU (1) AU2019355870B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021005914A2 (cg-RX-API-DMAC7.html)
CA (1) CA3114722A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021005738A2 (cg-RX-API-DMAC7.html)
IL (1) IL281811B2 (cg-RX-API-DMAC7.html)
MA (1) MA53043B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021003794A (cg-RX-API-DMAC7.html)
SG (1) SG11202102987VA (cg-RX-API-DMAC7.html)
TW (1) TWI821426B (cg-RX-API-DMAC7.html)
WO (1) WO2020072504A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230157981A (ko) * 2021-02-19 2023-11-17 칼비스타 파마슈티컬즈 리미티드 인자 xiia 저해제
EP4483954A1 (en) * 2023-06-29 2025-01-01 Masarykova Univerzita Substituted thieno [3,2-b]pyridines as inhibitors of protein kinases

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3763156A (en) * 1970-01-28 1973-10-02 Boehringer Sohn Ingelheim 2-heterocyclic amino-4-morpholinothieno(3,2-d)pyrimidines
US7375125B2 (en) * 1999-08-04 2008-05-20 Ore Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
WO2001010842A2 (en) * 1999-08-04 2001-02-15 Millennium Pharmaceuticals, Inc. Melanocortin-4 receptor binding compounds and methods of use thereof
FR2821356A1 (fr) * 2001-02-23 2002-08-30 Cerep Nouveaux derives d'arylcarbamates et d'arylurees, preparations et utilisations
SI2215094T1 (sl) * 2007-11-15 2016-05-31 Ym Biosciences Australia Pty Ltd N vsebujoče heterociklične spojine
AU2010210426B2 (en) * 2009-02-06 2015-06-11 Imago Pharmaceuticals, Inc. Inhibitors of Jun N-terminal kinase
KR20130131461A (ko) * 2011-03-07 2013-12-03 폰다지오네 텔레톤 Tfeb 변종 및 그의 용도
CA3199430A1 (en) * 2015-01-16 2016-07-21 The General Hospital Corporation Compounds for improving mrna splicing
WO2017112777A1 (en) * 2015-12-22 2017-06-29 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017192930A1 (en) * 2016-05-05 2017-11-09 Lysosomal Therapeutics Inc. SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS
CA3025943A1 (en) 2016-06-10 2017-12-14 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
KR20190070972A (ko) * 2016-11-02 2019-06-21 얀센 파마슈티카 엔.브이. Pde2 억제제로서의 [1,2,4]트리아졸로[1,5-a]피리미딘 유도체
WO2018118838A1 (en) * 2016-12-20 2018-06-28 Biomarin Pharmaceutical Inc. Ceramide galactosyltransferase inhibitors for the treatment of disease
BR112019023109A2 (pt) 2017-05-04 2020-05-26 Glenmark Pharmaceuticals S.A. Composto, composição farmacêutica e método para tratar uma doença, distúrbio, síndrome ou afecção mediada por nadph oxidase em um indivíduo
KR102736865B1 (ko) 2017-06-21 2024-12-03 샤이 테라퓨틱스 엘엘씨 암, 염증성 질환, 신경발달질환 및 섬유증 질환의 치료를 위하여 Ras 수퍼패밀리와 상호작용하는 화합물

Also Published As

Publication number Publication date
AU2019355870A1 (en) 2021-05-20
TWI821426B (zh) 2023-11-11
CO2021005738A2 (es) 2021-05-10
MX2021003794A (es) 2021-09-08
US11098056B2 (en) 2021-08-24
TW202035419A (zh) 2020-10-01
JP2022508523A (ja) 2022-01-19
JP7545979B2 (ja) 2024-09-05
CN113423711A (zh) 2021-09-21
KR102903997B1 (ko) 2025-12-26
BR112021005914A2 (pt) 2021-06-29
CN113423711B (zh) 2024-03-15
IL281811B1 (en) 2024-11-01
WO2020072504A1 (en) 2020-04-09
MA53043A1 (fr) 2022-08-31
US20200102324A1 (en) 2020-04-02
EP3861000A1 (en) 2021-08-11
SG11202102987VA (en) 2021-04-29
CA3114722A1 (en) 2020-04-09
IL281811A (en) 2021-05-31
IL281811B2 (en) 2025-03-01
KR20210087033A (ko) 2021-07-09
AU2019355870B2 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
MA58004B1 (fr) Dérivés de pyrazolyle utiles en tant qu'agents anticancéreux
MA58181B1 (fr) Composés tricycliques substitués
MA30412B1 (fr) Composés Pharmaceutiques
MA44721B1 (fr) Inhibiteurs de mcl1 macrocycliques pour le traitement du cancer
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
MA44674A (fr) Inhibiteurs de bromodomaine
MA34903B1 (fr) Derives de type azaindazole ou diazaindazole utilises comme medicaments
MA32070B1 (fr) Dérivés hétérocycliques réunis par fusion et procédés d'utilisation associés
EP2178870A4 (en) INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
MA37405A1 (fr) Composés hétérocyclyle
MA33886B1 (fr) Dérivés substitués d'acide carbamoylméthylamino-acétique utilisés comme nouveaux inhibiteurs de nep
PH12022551359A1 (en) Combination of an azetidine lpa1 receptor antagonist with pirfenidone and/or nintedanib for use in the treatment of fibrotic diseases
MA57412B1 (fr) Benzopyrrole substitués et inhibiteurs du complément structurellement apparentés
MA32135B1 (fr) Inhibiteurs de pim kinase et leurs procedes d'utilisation
AR051920A1 (es) Derivados de quinazolinona como inhibidores del parp, un procedimiento de preparacion, composicion farmaceutica y proceso de preparacion de esta
MA32009B1 (fr) Nouveaux derives de pyrazolo [3,4-d]pyrimidine en tant qu'agents anticancereux
MA29926B1 (fr) Derives de pyrazine
MA56674B1 (fr) Composés macrocycliques utilisés en tant qu'agonistes sting et procédés et utilisations de ceux-ci
MA46229A (fr) Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2
EA202192900A1 (ru) Модуляторы пути интегрированной реакции на стресс
MA49127B1 (fr) Dérivés d'indole n-substitués
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
MX2024001269A (es) Inhibidores de rock2 y sus usos.
ZA202006439B (en) Pyrazo-tetrahydroisoquinoline derivatives as dopamine d1 receptor positive modulators
MA53043A1 (fr) Dérivés de thiéno[3,2-b]pyridine utilisés en tant qu'inhibiteurs de l'udp-glycosyltransférase et procédés d'utilisation